Ignite Creation Date:
2024-05-05 @ 10:23 PM
Last Modification Date:
2024-10-26 @ 10:18 AM
Study NCT ID:
NCT01095744
Status:
COMPLETED
Last Update Posted:
2012-10-10
First Post:
2010-03-12
Brief Title:
Influence of Age on Amyloid Load in Alzheimers Disease and in Atypical Focal Cortical Alzheimers Disease
Sponsor:
Institut National de la Santé Et de la Recherche Médicale France
Organization:
Institut National de la Santé Et de la Recherche Médicale France
Study Overview
Official Title:
Influence of Age on amyloïd Load in Alzheimers Disease and in Atypical Focal Cortical Alzheimers Disease Like Posterior Cortical Atrophy PCA and Logopenic Progressive Aphasia LPAUsing Positron Emitting Tomography PET Imaging
Status:
COMPLETED
Status Verified Date:
2012-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BIOMAGE
Brief Summary:
The first objective is to asses influence of age on amyloid load measured by PET imaging using Pittsburgh B compound PiB radio-tracer in Alzheimers diseaseAD This will allow the determination of brains age-specific deterioration factors by comparing Early onset AD EOAD Late onset AD LOADand atypical focal cortical AD PCA and LPA The amount of brain lesions in AD patients is estimated by
1 measuring the rate of cortical brain atrophy
2 FDG imaging of glucose metabolism reflecting neuronal activity and
3 for patients who benefited from a lumbar puncture Cortical-spinal fluid CSF amounts of amyloïd and tau proteins are measured
1 measuring the rate of cortical brain atrophy
2 FDG imaging of glucose metabolism reflecting neuronal activity and
3 for patients who benefited from a lumbar puncture Cortical-spinal fluid CSF amounts of amyloïd and tau proteins are measured
Detailed Description:
Literature data suggests there are different types of AD depending on their age of onset called EOAD and LOAD These two categories are distinguished by the localization of brain atrophy severe and posterior in EOAD and more anterior in LOAD Neuro-pathologic data suggests some atypical focal cortical atrophy characterized by a respect of episodic memory may be classified within EOAD
PiB-based PET imaging allows the in-vivo visualization and quantification of amyloïd load
We want to answer the question whether the amount of amyloïd protein may be lower in LOAD than EOAD in patients showing the same level of dementia and thus identify ageing-specific cognitive disorders and understand witch factors influence etio-pathology of typical and atypical Alzheimers disease
PiB-based PET imaging allows the in-vivo visualization and quantification of amyloïd load
We want to answer the question whether the amount of amyloïd protein may be lower in LOAD than EOAD in patients showing the same level of dementia and thus identify ageing-specific cognitive disorders and understand witch factors influence etio-pathology of typical and atypical Alzheimers disease
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2008-A00939-46 | REGISTRY | IDRCB | None |